Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) EPS (Weighted Average and Diluted) (2021 - 2025)

Bioventus (BVS) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $0.21 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to $0.21, compared with a TTM value of $0.33 through Dec 2025, up 158.93%, and an annual FY2025 reading of $0.33, up 158.93% over the prior year.
  • EPS (Weighted Average and Diluted) was $0.21 for Q4 2025 at Bioventus, up from $0.05 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.21 in Q4 2025 and bottomed at -$1.28 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.19, with a median of -$0.08 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 41734.68% in 2022, then surged 162.5% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.0 in 2021, then tumbled by 41734.68% to -$0.23 in 2022, then skyrocketed by 60.87% to -$0.09 in 2023, then increased by 11.11% to -$0.08 in 2024, then soared by 362.5% to $0.21 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for BVS at $0.21 in Q4 2025, $0.05 in Q3 2025, and $0.11 in Q2 2025.